Antiprion Drugs as Chemical Tools to Uncover Mechanisms of Prion Propagation

References

• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129:2241 - 2265
   PubMed Web of Science ®Google Scholar
• Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74:4894 - 4897
   PubMed Web of Science ®Google Scholar
• Klingenstein R, Lober S, Kujala P, Godsave S, Leliveld SR, Gmeiner P, Peters PJ, Korth C. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 2006;
   PubMed Web of Science ®Google Scholar
• Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, Zahn R. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 2003; 46:3563 - 3564
   PubMed Web of Science ®Google Scholar
• Georgieva D, Schwark D, von Bergen M, Redecke L, Genov N, Betzel C. Interactions of recombinant prions with compounds of therapeutical significance. Biochem Biophys Res Commun 2006; 344:463 - 470
   PubMed Web of Science ®Google Scholar
• Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004; 116:121 - 137
   PubMed Web of Science ®Google Scholar
• Cuatrecasas P, Wilchek M, Anfinsen CB. Selective enzyme purification by affinity chromatography. Proc Natl Acad Sci USA 1968; 61:636 - 643
   PubMed Web of Science ®Google Scholar
• Lerman LS. A biochemically specific method for enzyme isolation. Proc Natl Acad Sci USA 1953; 39:232 - 236
   PubMed Web of Science ®Google Scholar
• Arsenis C, McCormick DB. Purification of liver flavokinase by column chromatography on flavin-cellulose compounds. J Biol Chem 1964; 239:3093 - 3097
   PubMed Web of Science ®Google Scholar
• McCormick DB. Specific purification of avidin by column chromatography on biotin-cellulose. Anal Biochem 1965; 13:194 - 198
   PubMed Web of Science ®Google Scholar
• Schnier JB, Kaur G, Kaiser A, Stinson SF, Sausville EA, Gardner J, Nishi K, Bradbury EM, Senderowicz AM. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett 1999; 454:100 - 104
   PubMed Web of Science ®Google Scholar
• Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, LeRoch K, Doerig C, Schultz P, Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem Biol 2000; 7:411 - 422
   PubMed Web of Science ®Google Scholar
• Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, Totzke F, Schachtele C, Lerman AS, Carnero A, Wan Y, Gray N, Meijer L. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280:31208 - 31219
   PubMed Web of Science ®Google Scholar
• Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H. Cellular targets of gefitinib. Cancer Res 2005; 65:379 - 382
   PubMed Web of Science ®Google Scholar
• Whitesell L, Mimnaugh EG, DeCosta B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91:8324 - 8328
   PubMed Web of Science ®Google Scholar
• Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. Synthesis and target identification of hymenialdisine analogs. Chem Biol 2004; 11:247 - 259
   PubMed Web of Science ®Google Scholar
• Knockaert M, Lenormand P, Gray N, Schultz P, Pouyssegur J, Meijer L. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 2002; 21:6413 - 6424
   PubMed Web of Science ®Google Scholar
• Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003; 100:15434 - 15449
   PubMed Web of Science ®Google Scholar
• Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, Aizawa S, Hatakeyama M, Ohba R, Hatori H, Yoshikawa T, Suzuki F, Oomori A, Tanaka H, Kawaguchi H, Watanabe H, Handa H. High-performance affinity beads for identifying drug receptors. Nat Biotechnol 2000; 18:877 - 881
   PubMed Web of Science ®Google Scholar
• Guiffant D, Tribouillard D, Gug F, Galons H, Meijer L, Blondel M, Bach S. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol J 2007; 2:68 - 75
   PubMedGoogle Scholar
• Sturgeon CM, Kemmer D, Anderson HJ, Roberge M. Yeast as a tool to uncover the cellular targets of drugs. Biotechnol J 2006; 1:289 - 298
   PubMedGoogle Scholar
• Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98:9836 - 9841
   PubMed Web of Science ®Google Scholar
• Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 2004; 22:62 - 69
   PubMed Web of Science ®Google Scholar
• Luesch H, Wu TY, Ren P, Gray NS, Schultz PG, Supek F. A genome-wide overexpression screen in yeast for small-molecule target identification. Chem Biol 2005; 12:55 - 63
   PubMed Web of Science ®Google Scholar
• Fields S, Song O. A novel genetic system to detect protein-protein interactions. Nature 1989; 340:245 - 246
   PubMed Web of Science ®Google Scholar
• Licitra EJ, Liu JO. A three-hybrid system for detecting small ligand-protein receptor interactions. Proc Natl Acad Sci USA 1996; 93:12817 - 12821
   PubMed Web of Science ®Google Scholar
• Eaglestone SS, Ruddock LW, Cox BS, Tuite MF. Guanidine hydrochloride blocks a critical step in the propagation of the prion-like determinant [PSI(+)] of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 2000; 97:240 - 244
   PubMed Web of Science ®Google Scholar
• Ferreira PC, Ness F, Edwards SR, Cox BS, Tuite MF. The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation. Mol Microbiol 2001; 40:1357 - 1369
   PubMed Web of Science ®Google Scholar
• Jung G, Masison DC. Guanidine hydrochloride inhibits Hsp104 activity in vivo: A possible explanation for its effect in curing yeast prions. Curr Microbiol 2001; 43:7 - 10
   PubMed Web of Science ®Google Scholar
• Jung G, Jones G, Masison DC. Amino acid residue 184 of yeast Hsp104 chaperone is critical for prion- curing by guanidine, prion propagation, and thermotolerance. Proc Natl Acad Sci USA 2002; 99:9936 - 9941
   PubMed Web of Science ®Google Scholar
• Grimminger V, Richter K, Imhof A, Buchner J, Walter S. The prion curing agent guanidinium chloride specifically inhibits ATP hydrolysis by Hsp104. J Biol Chem 2004; 279:7378 - 7383
   PubMed Web of Science ®Google Scholar
• Wegrzyn RD, Bapat K, Newnam GP, Zink AD, Chernoff YO. Mechanism of prion loss after Hsp104 inactivation in yeast. Mol Cell Biol 2001; 21:4656 - 4669
   PubMed Web of Science ®Google Scholar
• Zhou P, Derkatch IL, Liebman SW. The relationship between visible intracellular aggregates that appear after overexpression of Sup35 and the yeast prion-like elements [PSI(+)] and [PIN(+)]. Mol Microbiol 2001; 39:37 - 46
   PubMed Web of Science ®Google Scholar
• Bradley ME, Bagriantsev S, Vishveshwara N, Liebman SW. Guanidine reduces stop codon read-through caused by missense mutations in SUP35 or SUP45. Yeast 2003; 20:625 - 632
   PubMed Web of Science ®Google Scholar
• Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, Dormont D, Meijer L, Cullin C, Blondel M. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003; 21:1075 - 1081
   PubMed Web of Science ®Google Scholar
• Bach S, Tribouillard D, Talarek N, Desban N, Gug F, Galons H, Blondel M. A yeast-based assay to isolate drugs active against mammalian prions. Methods 2006; 39:72 - 77
   PubMed Web of Science ®Google Scholar
• Tribouillard D, Bach S, Gug F, Desban N, Beringue V, Andrieu T, Dormont D, Galons H, Laude H, Vilette D, Blondel M. Using budding yeast to screen for anti-prion drugs. Biotechnol J 2006; 1:58 - 67
   PubMedGoogle Scholar